Work

Study on Platelet-to-Leukocyte Ratio (PWR) Combined with Coagulation and Nutritional Markers for Predicting Survival and High Mortality Risk Factors in Patients with Advanced Malignancies

Year: 2026
Type: preprint
Abstract: Introduction There exists substantial interindividual heterogeneity in the prognosis of patients with advanced malignancies. Early and accurate identification of high-risk factors for mortality, together with the establishment of visual individualized predictive models (nomograms), carries critical clinical significance for optimizing therapeutic regimens and improving patients’ quality of life. Accumulating recent evidence has demonstrated that systemic pro-tumor inflammation, hypercoagulability, and cancer cachexia play central roles in tumor progression and cancer-related death. The platelet-to-leukocyte ratio (PWR, defined as PLT/WBC) serves as a novel composite biomarker that reflects the imbalance between coagulation and immunity. D-dimer and serum albumin (ALB) independently indicate the risk of hypercoagulable thrombosis and nutritional depletion, respectively. Nomograms convert multivariate Cox regression models into intuitive scoring graphs, enabling quantitative calculation of individualized survival probabilities. Methods This retrospective study analyzed de-identified clinical data from 109 patients with advanced malignancies. The platelet-to-leukocyte ratio (PWR) was calculated as PLT/WBC. Patient survival time (in months) and all-cause mortality status were recorded, along with peripheral laboratory parameters including PLT, WBC, PWR, RDW-CV, D-dimer, alanine transaminase (ALT), serum creatinine (CREA), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and albumin (ALB). The Kaplan–Meier method was used to generate survival curves, with log-rank tests applied for between-group comparisons. Univariate and multivariate Cox proportional hazards regression models were constructed to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). A nomogram was subsequently developed to predict individualized 6-month and 12-month overall survival probabilities. Results ① Overall survival distribution: Among the 109 patients with advanced malignancies, the median overall survival (Median OS) was 15.0 months (interquartile range [IQR], 5.5–32.0 months), and the mean OS was 28.12 ± 38.83 months.② D-dimer served as an independent high-risk factor for all-cause mortality༚Univariate Cox regression analysis revealed that D-dimer was a significant predictor of mortality (HR = 1.026, 95% CI: 1.005–1.048, p = 0.0137), indicating that each 1 mg/L increment in D-dimer corresponded to a 2.6% elevation in mortality risk. The median OS of patients in the highest tertile (T3 ≥ 6.7 mg/L) was merely 9.0 months, markedly shorter than that of patients in the low D-dimer group (16.0 months).③ Low platelet-to-leukocyte (PWR) ratio indicated dismal prognosis༚Patients in the lowest tertile (T1 < 13.7, low PWR) exhibited a median OS of only 8.5 months, suggestive of severe adverse survival outcomes.④ Quantitative prognostic nomogram model༚A visual nomogram integrating D-dimer, PWR, albumin, white blood cell count and age was established. This model allows intuitive calculation of individual total points and accurate estimation of 6-month and 12-month overall survival probabilities for each patient. Conclusion Elevated D-dimer (≥ 6.7 mg/L) and low platelet-to-leukocyte ratio (PWR, < 13.7) represent core high-risk biomarkers for mortality in patients with advanced malignancies. The established nomogram survival prediction model enables precise individualized estimation of survival risk, serving as a robust quantitative decision-making tool to guide clinical anticoagulation, anti-inflammatory therapy, and supportive care.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7233553893
Cites:
Cited by:
Related to: